Filters: Author is S Blower [Clear All Filters]
Transmission of zidovudine resistant strains of HIV-1: the first wave. AIDS. 15:2317-8.. 2001.
Predicting the future of XDR tuberculosis. Lancet Infect Dis. 7:443.. 2007.
Epidemiology, HIV and drugs: mathematical models and data. Br J Addict. 87:371-9.. 1992.
Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clin Infect Dis. 39 Suppl 5:S240-7.. 2004.
Calculating the consequences: HAART and risky sex. AIDS. 15:1309-10.. 2001.
Treatment Equity & the HIV epidemic in Africa. Nuntium by Bishop Rino Fisichella, Rector of the Pontifical Lateran University, Auxiliary of Rome, Pontifical Lateran University, The Vatican. 34. 2010.
Behaviour change and stabilization of seroprevalence levels in communities of injecting drug users: correlation or causation? J Acquir Immune Defic Syndr. 4:920-3.. 1991.
Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord. 3:345-53.. 2003.
HIV, drugs, and ecology. Science. 246:1236.. 1989.
Modelling the genital herpes epidemic. Herpes. 11 Suppl 3:138A-146A.. 2004.
What can modeling tell us about the threat of antiviral drug resistance? Curr Opin Infect Dis. 15:609-14.. 2002.
Sex and sample size. Lancet. 341:1023.. 1993.
Is population-level perversity a likely outcome of mass vaccination against HIV? - Authors reply Lancet Infect Dis. 5:255-256.. 2005.
Response. Science. 267:1252-3.. 1995.
Antibiotic resistance–to treat...(or not to treat)? Nat Med. 5:358.. 1999.
Mathematicians turn their attention to hepatitis C. Nat Med. 4:1233-4.. 1998.
Modeling the potential public health impact of imperfect HIV vaccines. J Infect Dis. 192:1494-5;authorreply1495-6.. 2005.
Targeting virological core groups: a new paradigm for controlling herpes simplex virus type 2 epidemics. J Infect Dis. 190:1610-7.. 2004.
Reply to "Comment on 'Linking population-level models with growing networks: a class of epidemic models'". Phys Rev E Stat Nonlin Soft Matter Phys. 74:046110.. 2006.
Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling. BMC Public Health. 9 Suppl 1:S11.. 2009.
The reinfection threshold does not exist. J Theor Biol. 235:151-2.. 2005.